SynthesisFrontiers in neurology2026
Efficacy and safety of edaravone dexborneol for acute ischemic stroke: a meta-analysis.
Synthesis in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the safety and efficacy of Edaravone Dexborneol in the treatment of acute ischemic stroke (AIS). Methods: Randomized clinical trials (RCTs) and Prospective cohort study on Edaravone Dexborneol for AIS were retrieved from PubMed, Embase, Cochrane Library, Web of Science, and CNKI. The quality of included studies was assessed using the Cochrane risk of bias tool. Meta-analysis was performed using RevMan 5.2. Efficacy evaluation is based on the changes in the National Institutes of Health Stroke Scale (NIHSS) and mRS scores from baseline to 10-14 days after treatment, as well as the proportion of patients achieving a modified Rankin Scale (mRS) score of 0-1 at 90 days. Safety evaluation is based on the incidence of adverse events during treatment or within 3 months. Results: The meta-analysis included 54 studies. For efficacy evaluation: 1. Compared with the control group, the edaravone dexborneol (ED) treatment group showed a reduction in NIHSS score of 2.27, which was statistically significant ( Conclusion: This meta-analysis provides evidence supporting the efficacy and safety of Edaravone Dexborneol for both short- and long-term treatment of acute ischemic stroke. It significantly reduced NIHSS and mRS scores at 10-14 days post-treatment and increased the proportion of patients achieving an mRS score of 0-1 at 90 days. Patients with higher baseline NIHSS scores may derive greater prognostic benefit from edaravone dexborneol therapy. Future multicenter, large-sample clinical studies are still needed to further validate the efficacy and safety of Edaravone Dexborneol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.